Collecting long-term safety and survival data from patients treated with Century Therapeutics cellular therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather long-term safety and survival data from participants who have previously been treated with a cellular therapy product in an eligible Century-sponsored index trial. The study focuses on monitoring for any late adverse events and assessing the persistence of the cellular therapy's effects. By collecting this data, researchers hope to identify any long-term risks associated with the treatment and ensure ongoing evaluation of patient safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
* Participants received at least one treatment with a cellular therapy product in an eligible index trial.
* Participant was withdrawn, early discontinued or completed an eligible index trial.
* Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

Exclusion Criteria:

-This study has no exclusion criteria.

Where it's running

• University of Maryland Medical Center
  Baltimore, Maryland, United States Recruiting
• Levine Cancer Institute
  Charlotte, North Carolina, United States Recruiting
• University of Cincinnati Medical Center
  Cincinnati, Ohio, United States Recruiting
• Swedish Cancer Institute
  Seattle, Washington, United States Recruiting
• Banner MD Anderson Cancer Center
  Gilbert, Arizona, United States Not yet recruiting
• University of Southern California - Norris Comprehensive Cancer Center
  Los Angeles, California, United States Not yet recruiting

Study contacts

• Study coordinator: Century Therapeutics Clinical Team
• Email: trial_response_century@centurytx.com
• Phone: 8885067670

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant

  This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07708987

• See if a behavioral coaching plus at-home exercise can help older blood cancer survivors slow aging

  Aimed at people 50 and older who have had a blood cancer, this trial tests whether combining coaching with a virtual exercise program can help slow aging and improve health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT07292272

• SIBP-A18 injection for advanced malignant solid tumors

  This will test whether SIBP-A18 injections are safe and can help adults with advanced solid tumors, including CLDN18.2-positive gastric, pancreatic, or biliary cancers.

  Recruiting Phase 1 Shanghai Institute Of Biological Products · Beijing, Beijing Municipality · NCT06985368

• 68Ga/177Lu-NRT6020 imaging and targeted therapy for FAP-positive advanced solid tumors

  This trial tests a PET imaging agent (68Ga-NRT6020) to find FAP-positive tumors and a linked radioactive treatment (177Lu-NRT6020) to see if it is safe and shows early benefit in adults with advanced solid tumors.

  Recruiting at 2 sites Phase 1 Chengdu New Radiomedicine Technology Co. LTD. · Shanghai and 1 other locations · NCT06911489

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.